American Pfizer resists and presses the lower shelf of medicine Found may increase the death risk

American Pfizer resists and presses the lower shelf of medicine Found may increase the death risk


Lie in the building of general headquarters of Pfizer drugmaker of New York of U.S.A..
The European medicines administration bureau announces on the 10th, begin to examine the security of the growth hormone medicine to sell on the market of European Union. French medicine regulator is observed to discover, taking this kind of medicine may increase the death risk. The relevant medicine coming to the company, Swiss Novartis Company in American Pfizer pharmacy Co., Ltd., U.S.A. gift will be examined.
On the same day, Pfizer drugmaker announces, the medicine Thelin against lung artery hypertension withdraws from the market, the reason is that this kind of medicine may cause the liver of mortality to damage.
The medicine is on trial
European medicines administration bureau said in a statement: "We will examine all data about growth hormone, benefited for what has been assessed this kind of medicine again and the side effect is balanced. "
Include Genotropin of Pfizer in the growth hormone medicine of the market sales of European Union member state, Humatrope,etc. that the company comes in Omnitrope, gift which enterprises produce under Novartis Company.
Omnitrope2006 is approved listing, the growth hormone medicine that it is first kind of entry European Union market by European medicines administration bureau every year.
Growth hormone can promote the health of a person from childhood to adolescence to grow, influence the organism to deal with the ability of protein, fat and carbohydrate at the same time.
The growth hormone medicine is by DNA (DNA) The recombinant technique is made, is used for treating the organism to secrete growth hormone insufficiently and short and small, congruence that also include Tener's syndrome and chronic renal function.

|